ArticleCurrent topics in medicinal chemistry2026
The Diagnostic Role and Potential Pharmacological Value of DDR1 in Pan-Cancer.
Article in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionCancer remains a devastating global health burden. Despite the identification of numerous biological targets, effective therapeutic agents remain limited. As a highly promising novel target, the role of Discoid Domain Receptors (DDRs) in pan-cancer biology is still poorly characterized. Thus, this study aims to elucidate the regulatory mechanisms and diagnostic potential of DDR1 across different cancer types.
methodsHerein, we used UCSC, SangerBox, GEPIA, GSCA, and GeneMANIA online databases to analyze the expression and role of DDR1 in pan-cancer.
resultsThe expression levels of DDR1 showed significant differences in some tumour T, N, and M stages. Importantly, DDR1 expression was associated with clinical prognosis in five cancers. In addition, DDR1 was inversely correlated with most immune checkpoint pathways, immunomodulatory genes, and immune cell infiltration in a few cancers. Furthermore, in most cancers, DDR1 promotes cancer progression by promoting apoptosis, inhibiting cell cycle and EMT, activating hormone AR activity, activating PI3K/AKT pathway, RASMAPK pathway, and RTK pathway. Finally, we also found that the DDR1 gene was positively associated with stemness scores in most tumors.
conclusionOur findings demonstrate that DDR1 exhibits diagnostic utility and holds promising translational potential as a therapeutic target across multiple cancer types.
Indexed as
Identifiers
40676791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.